Close
Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Symposium Spotlight: Biomarkers in MND – improving drug development and clinical trial design

Reading Time: 4 minutes Diagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that these three things are essential requirements for treating all diseases. But how can we achieve this? The answer may lie in biomarkers. In his plenary talk at last year’s International…

Virtual Symposium: Phase 3 clinical trial results – levosimendan

Virtual Symposium: Phase 3 clinical trial results – levosimendan

Reading Time: 2 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials. Presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General Hospital,…

Virtual Symposium: Results from the Phase 3 clinical trial of NurOwn

Virtual Symposium: Results from the Phase 3 clinical trial of NurOwn

Reading Time: 4 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials Co-presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General…

Targeting Tregs: IMODALS study paves the way for MIROCALS
A colorized scanning electron micrograph of a T lymphocyte. Credit: NIAID

Targeting Tregs: IMODALS study paves the way for MIROCALS

Reading Time: 4 minutes Although ALS is a neurodegenerative disease, researchers are increasingly also interested in events happening outside the brain and spinal cord, in particular whether changes in the immune system might play a role in influencing the course of the disease. This is a subject we’ve covered before, with particular reference to the ongoing MIROCALS drug trial…

TUDCA-ALS has started recruiting in the UK

TUDCA-ALS has started recruiting in the UK

Reading Time: 3 minutes TUDCA-ALS is a European Consortium (funded by the European Commission under the Horizon 2020 grant) involving top researchers from seven countries across Europe (see Figure 1). The Consortium aims to find a new treatment to slow down the progression of MND/ALS by conducting a clinical trial to investigate the safety and efficacy (effectiveness) of Tauroursodeoxycholic…